The risk factors for production of extended-spectrum β-lactamases (ESBLs) have rarely been studied for bloodstream infections of Escherichia coli alone. A case-control study was undertaken to identify the risk factors associated with bloodstream infections caused by ESBLproducing E. coli. METHODS: From January 1, 2005 to June 30, 2007, all patients with a confirmed diagnosis of bloodstream infection caused by ESBL-producing E. coli were reviewed. Each patient was matched with one control subject who experienced ESBL-negative E. coli bacteremia during the same study period. RESULTS: Of the 97 patients diagnosed with ESBL-producing E. coli bacteremia, six were excluded owing to incomplete follow-up and missing data. Comparisons were made between 91 patients and their controls. Multivariate analysis identified urinary catheterization [odds ratio (OR) = 6.21, 95% confidence interval (CI) = 1.91-20.25; p = 0.003], prior exposure to antibiotics (OR = 2.93, 95% CI = 1.18-7.30; p = 0.021) and previous treatment with oxyimino-cephalosporins (OR = 5.16, 95% CI = 1.03-25.79; p = 0.046) as independent predictors for bloodstream infection by ESBL-producing E. coli. Conversely, patients classified as having a community-acquired infection were less likely to acquire bacteremia caused by ESBL-producing E. coli than those caused by non-ESBL-producing E. coli (OR = 0.22, 95% CI = 0.09-0.57; p = 0.002). CONCLUSION: More judicious use of antimicrobial agents, especially oxyimino-cephalosporins, and avoidance of urinary catheterization may decrease the possibility of ESBL-producing E. coli bacteremia in hospitalized patients.
Introduction
Extended-spectrum β-lactamases (ESBLs) are plasmidmediated bacterial enzymes that are able to hydrolyze oxyimino-β-lactams (broad-spectrum cephalosporins and aztreonam). The marked increase in the incidence of infections due to ESBL-producing Enterobacteriaceae in recent years is of great concern, since the therapeutic options for these organisms are limited. 1, 2 The emergence of CTX-M β-lactamases, especially in Escherichia coli, has enabled the expansion of this infection in both nosocomial and community settings. 3 Furthermore, patients with infections caused by ESBL producers may experience delay in the initiation of appropriate therapy compared with patients with non-ESBL infections. 4 The subsequent increased risks for clinical failure and death have been shown in several studies. [5] [6] [7] [8] [9] [10] Documenting risk factors and identifying vulnerable patient groups are important for the management and control of severe infections due to ESBLproducing organisms. The risk factors for acquisition of ESBLs have been studied for Klebsiella pneumoniae, or multiple infections due to Enterobacteriaceae species, 11-14 but rarely for E. coli alone. Data focusing on ESBL-producing E. coli bloodstream infection are scarce. In Taiwan, the prevalence of ESBLs has risen in the past decade, ranging from 1.5% to 21.9% for various clinical isolates of E. coli. [15] [16] [17] Although the risk factors for infection by ESBL-producing K. pneumoniae and other Enterobacteriaceae have been investigated in a few studies, 18, 19 no published data dealing with E. coli infection alone is available. The objective of this study was to elucidate the possible risk factors for ESBL production in patients with E. coli bacteremia.
Methods

Data collection
This study was conducted at National Taiwan University Hospital, a 2,500-bed major teaching hospital in northern Taiwan that provides both primary and tertiary medical care. 
Bacteriology and antimicrobial susceptibility testing
Strains of E. coli were identified by standard microbiologic methods in the microbiology laboratory. Antimicrobial susceptibility testing was performed using the Kirby-Bauer disk diffusion method. Production of ESBL was confirmed using the double-disk synergy test in accordance with the Clinical and Laboratory Standards Institute standards.
21
Definitions
The date of collection of the first blood culture which yielded E. coli was regarded as the date of bacteremia onset. Nosocomial infection was defined as an infection that occurred > 48 hours after admission to the hospital, or an infection that occurred < 48 hours after admission in patients that had been transferred from another hospital. Infection with ESBL-producing E. coli detected within the first 48 hours of hospitalization was classified as "community-onset" in accordance with the US Centers for Disease Control and Prevention definition 22 and were further classified into community-acquired or healthcareassociated infections (modified from the study of SiegmanIgra et al). 23 The former definition represents truly community-acquired infection, while the latter consists of infections in patients recently discharged (≤ 6 months), infections associated with invasive procedures performed just before, or at the time of, admission and infections in patients admitted from nursing homes. The primary sites of infection were identified according to the Centers for Disease Control and Prevention definitions. 24 Patients were classified as immunosuppressed if neutropenia (defined as < 1,000 polymorphonuclear neutrophils cells/mm 3 ), hematologic malignancy, corticosteroid therapy (equivalent to > 20 mg prednisolone/day) for at least 2 weeks, and/or cancer chemotherapy or radiation therapy were documented within 30 days of the onset of bacteremia. Patients with serum creatinine level > 3mg/dL, or under dialysis, before the onset of bacteremia were considered to have chronic renal insufficiency.
Statistical analysis
All statistical analyses were performed using the SAS software package (version 9.1; SAS Institute Inc., Cary, NC, USA). For univariate analysis, categorical variables were compared using χ 2 or Fisher's exact test and continuous variables were analyzed with Student's t test or MannWhitney U test. A p value < 0.05 was considered to be statistically significant, and all probabilities were two-tailed. Multivariate analysis was used to identify independent risk factors for ESBL production and was conducted using a stepwise logistic regression method.
Results
During the study period, 1,792 adult inpatients were diagnosed with E. coli bacteremia. Of these, 97 (5.4%) were identified as having bloodstream infections caused by ESBL-producing E. coli. Six patients were excluded owing to incomplete medical records. The baseline characteristics of the remaining 91 patients and the 91 controls are shown in Table 1 . By univariate analysis, case patients had a higher Charlson comorbidity index (3.9 ± 2.5 vs. (Table 3) .
Discussion
Early identification of ESBL production is becoming increasingly important in terms of appropriate treatment and effective infection control in hospitals. Our study confirms that patients with urinary catheterization and previous use of antimicrobial agents, especially oxyiminocephalosporins, are at risk of acquiring bloodstream infection due to ESBL-producing E. coli compared with non-ESBL-producing E. coli bacteremia, a result similar to that in previous reports. [25] [26] [27] In previous studies, prior exposure to fluoroquinolone was also identified as a potential risk factor. 26, 28 Although this factor was not revealed as an independent risk factor for acquiring ESBL-producing E. coli bacteremia by multiple analysis in the present study, fluoroquinolone was the second most frequently used class of antibiotics (25.3%) before bacteremia onset in our case group. This may partially explain the low susceptibility rate of the ESBL-producing E. coli to fluoroquinolone (38.5%) in our hospital (data not shown). It should be noted that, unlike the situations observed in other multidrug resistant bacteria, underlying diseases, e.g. diabetes mellitus, liver cirrhosis and chronic renal insufficiency, were not shown to increase the risk for acquiring bloodstream infections of ESBL-producing E. coli. This is consistent with previous studies which demonstrated that antibiotic selective pressure, rather than individual comorbidities, was the most important factor in the emergence of ESBL-producing isolates. 12, 26, [28] [29] [30] [31] Furthermore, hospitals and other health-care institutions remain the major settings for spreading these multidrug resistant strains according to our study. These findings strong support the implementation of effective strategies to limit the use of extended-spectrum antibiotics and the use of invasive procedures, including the insertion of a urinary catheter, to control the spread of ESBL-producing E. coli. Although community-acquired infections (OR = 0.22, 95% CI = 0.09-0.57; p = 0.002) were a negative predictor of ESBL production, it is still a matter of concern that 8.8% of case patients were classified as having strictly defined community-acquired infections, and the proportion seems to be increasing in our hospital (9% in 2006 vs. 12% in 2007). In fact, the emergence of ESBL-producing E. coli in the community has been increasingly recognized as a global problem in recent years. [32] [33] [34] The majority of cases were attributed to isolates harboring CTX-M type β-lactamases, a fact which has also raised considerable concern in hospital settings. 36 In many countries, including Taiwan, CTX-M enzymes have become the most prevalent ESBLs among E. coli isolates. 3, 37, 38 In our study population, none of the patients classified as having community-acquired infections were exposed to antimicrobial agents within the 30 days prior to the onset of bacteremia. In a recent study by Kang et al, no predisposing factor was identified in up to 57% of patients having community-onset bloodstream infections caused by ESBL-producing E. coli. 39 The paucity of identifiable risk factors for the acquisition of ESBLs poses a great challenge for clinical therapeutics and infection control in this specific population. There are limitations in our present study. First, the possible coproduction of AmpC enzymes in strains of E. coli might result in false negative tests for the detection of ESBLs using standard Clinical and Laboratory Standards Institute methods. 17, 37 Second, pulsed-field gel electrophoresis was not performed to determine the genetic similarities between all of the identified ESBL-producing E. coli. Consequently, we may have underestimated the possibility of clonal spread of these resistant isolates within the hospital. Finally, our study was conducted at a single tertiary care hospital and our results may not reflect those at other institutions with different epidemiologies.
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In conclusion, the incidence of ESBL-producing E. coli bacteremia may be reduced by curtailing the use of oxyimino-cephalosporins and avoiding urinary catheterization. Although hospitals remain the major settings in which ESBL-producing E. coli bacteremia occur, the emergence of ESBL-producing organisms in the community warrants further investigation of the epidemiology and risk factors within this population. 
